Chimeric Antibody Market to Reach USD $23.34 Billion by 2030 at 11.3% CAGR
Chimeric Antibody Market Growth
Chimeric Antibody Market Segmentation
Chimeric Antibody Market Trends
The Business Research Company's Chimeric Antibody Market to Reach USD $23.34 Billion by 2030 at 11.3% CAGR
LONDON, GREATER LONDON, UNITED KINGDOM, May 1, 2026 /EINPresswire.com/ -- "Chimeric Antibody market to surpass $23 billion in 2030. In comparison, the Gene Therapy market, which is considered as its parent market, is expected to be approximately $36 billion by 2030, with Chimeric Antibody to represent around 65% of the parent market. Within the broader Pharmaceuticals industry, which is expected to be $2,513 billion by 2030, the Chimeric Antibody market is estimated to account for nearly 1% of the total market value.
Which Will Be The Biggest Region In The Chimeric Antibody Market In 2030?
North America will be the largest region in the chimeric antibody market in 2030, valued at $10 billion. The market is expected to grow from $6 billion in 2025 at a compound annual growth rate (CAGR) of 11%. The rapid growth can be attributed to the presence of advanced biopharmaceutical infrastructure across the United States and Canada, rising prevalence of chronic and autoimmune diseases, increasing adoption of targeted biologic therapies, strong investments in antibody research and development, and favorable regulatory frameworks that support accelerated drug approvals and innovation in monoclonal antibody technologies.
Which Will Be The Largest Country In The Global Chimeric Antibody Market In 2030?
The USA will be the largest country in the chimeric antibody market in 2030, valued at $9 billion. The market is expected to grow from $5 billion in 2025 at a compound annual growth rate (CAGR) of 11%. The rapid growth can be attributed to strong manufacturing capabilities for large-scale biologics production, increasing adoption of biosimilars improving treatment accessibility, growing collaborations between biotech firms and academic research institutions, rising focus on developing next-generation antibody formats, and continuous expansion of specialty treatment centers supporting advanced biologic therapies.
Request A Free Sample Of The Chimeric Antibody Market Report
https://www.thebusinessresearchcompany.com/sample_request?id=27253&type=smp&utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Apr_PR
What Will Be The Largest Segment In The Chimeric Antibody Market In 2030?
The chimeric antibody market is segmented by type into immunoglobulin G chimeric antibodies, fragment antigen-binding chimeric antibodies, and single-chain variable fragment chimeric antibodies. The immunoglobulin G chimeric antibodies market will be the largest segment of the chimeric antibody market segmented by type, accounting for 77% or $18 billion of the total in 2030. The immunoglobulin G chimeric antibodies market will be supported by their high stability and longer half-life, widespread use in cancer and autoimmune disease treatments, strong clinical efficacy and safety profiles, increasing approvals of monoclonal antibody drugs, and continuous advancements in antibody engineering to enhance therapeutic performance and patient outcomes.
The chimeric antibody market is segmented by manufacturing process into recombinant deoxyribonucleic acid (DNA) technology, hybridoma technology, and phage display technology.
The chimeric antibody market is segmented by mode of administration into intravenous (IV) administration, subcutaneous administration, and intramuscular administration.
The chimeric antibody market is segmented by application into cancer therapy, autoimmune diseases, infectious diseases, and transplant rejection.
The chimeric antibody market is segmented by end user into pharmaceutical companies, research institutes, and clinics and hospitals.
What Is The Expected CAGR For The Chimeric Antibody Market Leading Up To 2030?
The expected CAGR for the chimeric antibody market leading up to 2030 is 11%.
What Will Be The Growth Driving Factors In The Global Chimeric Antibody Market In The Forecast Period?
The rapid growth of the global chimeric antibody market leading up to 2030 will be driven by the following key factors that are expected to reshape biologic drug development strategies, therapeutic targeting approaches, antibody engineering innovations, prevalence of autoimmune diseases, and treatment protocols across the global healthcare industry.
Increasing Prevalence Of Autoimmune Diseases And The Limitations Of Current Therapies - The increasing prevalence of autoimmune diseases and the limitations of current therapies is expected to become a key growth driver for the chimeric antibody market by 2030. Traditional treatment options often provide limited efficacy and are associated with adverse side effects, prompting the need for more targeted and effective biologic therapies. Chimeric antibodies offer improved specificity and reduced off-target effects, making them highly suitable for managing complex autoimmune conditions. Pharmaceutical companies are therefore investing in the development of advanced antibody-based therapies to address unmet medical needs. This growing reliance on targeted biologics is reinforcing sustained market expansion. As a result, the increasing prevalence of autoimmune diseases and the limitations of current therapies is anticipated to contribute approximately 3.0% annual growth to the market.
Rising Prevalence Of Chronic Diseases - The rising prevalence of chronic diseases is expected to emerge as a major factor driving the expansion of the chimeric antibody market by 2030. Conditions such as cancer, cardiovascular diseases, and inflammatory disorders are increasing globally, creating significant demand for advanced therapeutic solutions. Chimeric antibodies play a crucial role in targeted treatment approaches, particularly in oncology and immunology. Continuous advancements in diagnostic technologies and early disease detection are further supporting the adoption of antibody-based therapies. Consequently, the rising prevalence of chronic diseases is projected to contribute around 2.8% annual growth to the market.
Growing Demand For Targeted Therapies - The growing demand for targeted therapies is expected to act as a key growth catalyst for the chimeric antibody market by 2030. Precision medicine approaches are gaining traction as healthcare providers seek treatments that offer higher efficacy with minimal side effects. Chimeric antibodies enable selective targeting of disease-specific antigens, improving treatment outcomes and patient safety. Increasing investments in personalized medicine, along with advancements in biotechnology and genomics, are further accelerating the development and adoption of targeted biologics. Therefore, the growing demand for targeted therapies is projected to contribute approximately 2.5% annual growth to the market.
Access The Detailed Chimeric Antibody Market Report Here
https://www.thebusinessresearchcompany.com/report/chimeric-antibody-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Apr_PR
What Are The Key Growth Opportunities In The Chimeric Antibody Market In 2030?
The most significant growth opportunities are anticipated in the immunoglobulin G chimeric antibodies market, the fragment antigen-binding chimeric antibodies market, and the single-chain variable fragment chimeric antibodies market. Collectively, these segments are projected to contribute over $10 billion in market value by 2030, driven by increasing demand for targeted biologic therapies, rising prevalence of cancer and autoimmune diseases, continuous advancements in antibody engineering and drug development technologies, and expanding clinical applications of monoclonal antibodies across multiple therapeutic areas. This momentum reflects the healthcare industry’s focus on improving treatment efficacy, advancing precision medicine, and addressing unmet clinical needs, accelerating growth across the global chimeric antibody ecosystem.
The immunoglobulin G chimeric antibodies market is projected to grow by $8 billion, the fragment antigen-binding chimeric antibodies market by $1 billion, and the single-chain variable fragment chimeric antibodies market by $1 billion over the next five years from 2025 to 2030.
Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. We have published over 17,500 reports across 27 industries and 60+ geographies. Our research is powered by 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.
We provide continuous and custom research services, offering a range of specialized packages tailored to your needs, including Market Entry Research Package, Competitor Tracking Package, Supplier & Distributor Package and much more.
Disclaimer: Please note that the findings, conclusions and recommendations that TBRC Business Research Pvt Ltd delivers are based on information gathered in good faith from both primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such TBRC Business Research Pvt Ltd can accept no liability whatever for actions taken based on any information that may subsequently prove to be incorrect. Analysis and findings included in TBRC reports and presentations are our estimates, opinions and are not intended as statements of fact or investment guidance."
Oliver Guirdham
The Business Research Company
info@tbrc.info
+44 7882 955267
Visit us on social media:
LinkedIn
Facebook
X
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
